Keymed Presents Results of Phase 1 Study on Gastric/Gastroesophageal Cancer Drug; Shares Fall 3%

MT Newswires Live06-03

Keymed Biosciences (HKG:2162) presented results of its phase 1 clinical study for its CMG901 treatment for advanced gastric/gastroesophageal junction cancer at the meeting of the American Society of Clinical Oncology, according to a Monday filing with the Hong Kong Stock Exchange.

Shares slid nearly 3% in Hong Kong during Monday's morning trading.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment